3
Announcements
Trials
Browse
Landscape
Status
Completed
159
Terminated
32
Recruiting
21
Withdrawn
7
Unknown
7
Not yet recruiting
6
Active not recruiting
6
No longer available
3
Approved for marketing
2
Available
1
Sponsor Class
INDUSTRY
2
Study Type
Expanded_access
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Carcinoma, Non-Small-Cell Lung
11
Recurrence
9
Neoplasms
6
Multiple Myeloma
6
Breast Neoplasms
6
Small Cell Lung Carcinoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
HER2-positive Breast Cancer
3
Glioma
3
Carcinoma, Medullary
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Waldenstrom Macroglobulinemia
1
Urogenital Neoplasms
1
Tumors Harboring NTRK Fusion
1
Interventions
ponatinib
1
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Approved for marketing
×
INDUSTRY
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Clear all
NCT01592136
2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT00905593
2012-07-18
ENACT
Novartis
Approved for marketing